Short answer
KPV is a 3-amino-acid fragment of α-MSH; BPC-157 is a 15-amino-acid synthetic peptide. Both are listed by FDA among compounding substances that may present significant safety risks [FDA 2026]. Neither is an approved drug. BPC-157 has a handful of small uncontrolled human reports[Poolton 2026]; KPV has no human data at all [FDA briefing 2026]. No study compares the two.
KPV vs BPC-157 at a glance
KPV and BPC-157 compared| Property | KPV | BPC-157 |
|---|
| Length | 3 amino acids | 15 amino acids |
|---|
| Sequence | Lys-Pro-Val | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
|---|
| Formula (free form) | C16H30N4O4 | C62H98N16O22 |
|---|
| Molecular weight | 342.43 g/mol | 1419.5 g/mol |
|---|
| PubChem CID | 125672 | 9941957 |
|---|
| Origin | C-terminal residues 11–13 of α-MSH | Synthetic pentadecapeptide (“body protection compound”) |
|---|
| Main research models | Intestinal, skin, airway and fever models; cells and rodents | Largely animal models, per a 2026 systematic review |
|---|
| Human studies | None published | Three small uncontrolled studies (n=30 total) |
|---|
| FDA Category 2 list | Listed | Listed |
|---|
| Use FDA evaluated (July 2026) | Wound healing and inflammatory conditions | Ulcerative colitis |
|---|
| WADA | S0 non-approved substance | S0 non-approved substance |
|---|
Identity data: PubChem [PubChem][PubChem]. Both formulas were checked against their sequences. Regulatory rows: FDA [FDA 2026][FDA PCAC 2026], WADA [WADA 2026].
Research models
KPV research centres on inflammatory signalling in intestinal cells and chemically induced colitis in rodents [Dalmasso 2008], plus skin, airway and fever models (see the studies database). BPC-157’s literature is larger and, according to a 2026 systematic review, largely limited to animal models [Poolton 2026]. Different models, endpoints and forms mean results from one cannot be read across to the other.
Human evidence
A 2026 systematic review found three BPC-157 human studies totalling 30 participants, all without a control group [Poolton 2026], including a two-person intravenous safety pilot [Lee 2025] and a twelve-person bladder pilot [Lee 2024]. Studies this small and uncontrolled cannot establish efficacy or safety. For KPV, FDA found no human studies by any route [FDA briefing 2026].
Regulatory status
At its July 2026 meeting, FDA’s compounding advisory committee considered both substances, KPV for wound healing and inflammatory conditions and BPC-157 for ulcerative colitis [FDA PCAC 2026]. Committee votes are advisory; until FDA completes rulemaking, neither is on the 503A bulks list. Full regulatory detail.
Frequently asked questions
Is KPV better than BPC-157?
That cannot be answered. Neither has been compared with the other in any study, and neither has controlled human efficacy data. They are different molecules studied in different models.
Can KPV and BPC-157 be combined?
No study has tested the combination in humans or in a controlled animal design, so nothing is known about combining them. This site does not provide stacking guidance.
Which has more human data?
BPC-157 has a few small uncontrolled human reports (three studies, 30 participants in total, in a 2026 systematic review). KPV has none.